- Global Phase 2 placebo-controlled trial enrolled twice as fast as the industry average, establishing a roadmap for future studies - - Enrollment initiated in Cohort 2 of CDx+ patients to evaluate the company’s companion diagnostic - -  Both APOLLO-CD and ARTEMIS-UC topline results on track for

- Enrollment completed ahead of schedule for APOLLO-CD Phase 2a study of PRA023 in Crohn’s disease patients - - ARTEMIS-UC Phase 2 Cohort 1 enrollment on track with completion expected 3Q 2022 - - Both APOLLO-CD and ARTEMIS-UC topline results expected 4Q 2022 – SAN DIEGO, June 08, 2022 (GLOBE

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of

- Advanced and expanded development of PRA023 across three immune-mediated indications - - Topline results from ARTEMIS-UC and APOLLO-CD Phase 2 studies on track for fourth quarter 2022 - - Announced key appointments in Leadership Team - - Strong cash position of $227 million as of March 31, 2022 -

- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways - - ATHENA-SSc-ILD Phase 2 topline results expected first-half 2024 - - FDA has granted Fast Track Designation for PRA023 for the treatment of SSc-ILD - SAN DIEGO, March 30, 2022 (GLOBE

- Topline results for ongoing Phase 2 clinical trial in ulcerative colitis and Phase 2a trial in Crohn’s disease expected in fourth quarter 2022 - - Phase 2 trial in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) on track to initiate this quarter - - Signed agreement with Ypsomed

SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment

- Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) - - New patent granted for PRA023 companion diagnostic (CDx) reinforces Prometheus’ precision approach and extends CDx patent

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment